Gene transfer in experimental medicine

Drug News and Perspectives

Volumn 16, Issue 5, 2003, Pages 267-276

  Romano, Gaetano ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; RETROVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DNA VECTOR; GENE THERAPY; GENE TRANSFER; HEART DISEASE; HUMAN; HUNTINGTON CHOREA; IMMUNIZATION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; MONOGENIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; REVIEW; SPINAL CORD INJURY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMAN EXPERIMENTATION; HUMANS;

EID: 0141728485     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.5.829314     Document Type: Review

References (83)

1. Blaese, R.M., Culver, K.W., Miller, A.D. et al. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 1995, 270: 475-80.
2. Romano, G., Micheli, P., Pacilio, C. and Giordano, A. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000, 18: 19-39.
3. Knorr, D. Serious adverse event on NIH human gene transfer protocol n. 9512-139. A phase I study of adenovector mediated gene transfer to liver in adults with partial ornitine transcarbamylase deficiency. Memorandum of 21 September 1999, Office of Recombinant DNA activities at NIH.
4. Brenner, M. Gene transfer by adenovectors. Blood 1999, 94: 3965-7.
5. Anderson, W.F. The best of times, the worst of times. Science 2000, 288: 627-9.
6. Anderson, W.F. Gene therapy scores against cancer. Nat Med 2000, 6: 862-3.
7. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G. et al. Gene therapy of human severe combined immunodeficiency (SCID)-XI disease. Science 2000, 288: 669-72.
8. Buckley, R.H. Gene therapy for human SCID: Dreams become reality. Nat Med 2000, 6: 623-4.
9. Marshall, E. Gene therapy a suspect in leukemia-like disease. Science 2002, 298: 34-5.
10. Buckley, R.H. Gene therapy for SCID-A complication after remarkable progress. Lancet 2002, 360: 1185-6.
11. Check, E. Second cancer case halts gene-therapy trials. Nature 2003, 421: 305.
12. Li, Z., Dullmann, J., Schiedlmeier, B. et al. Murine leukemia induced by retroviral gene marking [Letter]. Science 2002, 296: 497.
13. Donsante, A., Vogler, C., Muzyczka, N. et el. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001, 8: 1343-6.
14. Daly, T.M., Ohlemiller, K.K., Roberts, M.S. et al. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther 2001, 8: 1291-8.
15. Kay, M.A., Manno, C.S., Ragni, M.V. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000, 24: 257-61.
16. Roth, D.A., Tawa, N.E., O'Brien, J.M. et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001, 344: 1773-9.
17. Isner, J.M. and Asahara, T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999, 103: 1231-66.
18. Walker, R.E., Bechtel, C.M., Natarajan, V. et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000, 96: 467-74.
19. Mitsuyasu, R.T., Anton, P.A., Deeks, S.G. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000, 96: 785-93.
20. Kang, W.K., Park, C., Yoon, H.L. et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study. Hum Gene Ther 2001, 12: 671-84.
21. Roth, J.A. and Cristiano, R.J. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997, 89: 21-39.
22. Khuri, F.R., Nemunaitis, J., Ganly, I. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6: 879-85.
23. Leone, P., Janson, C.G., Bilaniuk, L. et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000, 48: 27-38.
24. Anderson, W.F. Excitement in gene therapy. Hum Gene Ther 2001, 12: 1483-4.
25. Costantini, L.C., Bakowska, J.C., Brekefield, X.O. and Isacson, O. Gene therapy in the CNS. Gene Ther 2000, 7: 93-109.
26. Alisky, J.M. and Davidson, B.L. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum Gene Ther 2000, 11: 2315-29.
27. Ferber, S., Halkin, A., Cohen, H. et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin and amelio-rates streptozotocin-induced hyperglycemia. Nat Med 2000, 6: 568-72.
28. Gros, L., Riu, E., Montoliu, L. et al. Insulin production by engineering muscle cells. Hum Gene Ther 1999, 10: 1207-17.
29. Ueki, K., Yamauchi, T., Tamemoto, H. et al. Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy. J Clin Invest 2000, 105: 1437-45.
30. Tiedge, M., Elsner, M., McCleghan, N.H. et al. Engineering of a glucose-responsive surrogate cell for insulin replacement therapy of experimental insulin-dependent diabetes. Hum Gene Ther 2000, 11: 403-14.
31. Esperanza, J. and Bhamarapravati, N. Accelerating the development and future availability of HIV-I vaccines: Why, when, and how? Lancet 2000, 355: 2061-6.
32. Ugen, K.E., Nyland, S.B., Boyer, J.D. et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998, 16: 1818-21.
33. Gojo, S., Cooper, D.K., Iacomini, J. and LeGuern, C. Gene therapy and transplantation. Transplantation 2000, 69: 1995-9.
34. Dick, J.E. Gene therapy turns the corner. Nat Med 2000, 6: 624-6.
35. Romano, G., Pacilio, C. and Giordano, A. Gene transfer technology in therapy: Current applications and future goals. Stem Cells 1999, 17: 191-202.
36. Soneoka, Y., Cannon, P.M., Ramsdale, E.E. et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucl Acids Res 1995, 23: 628-33.
37. Xu, Z.-L., Mizuguchi, H., Ishii-Watabe, A. et al. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 2001, 272: 149-56.
38. Lacy-Hulbert, A., Thomas, R., Li, X.-P. et al. Interruption of coding sequences by heterologous introns can enhance the functional expression of recombinant genes. Gene Ther 2001, 8: 649-53.
39. Pear, W.S., Nolan, G.P., Scott, M.L. and Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90: 8392-6.
40. Yang, S., Delgado, R., King, S.R. et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999, 10: 123-32.
41. Urabe, M., Ding, C. and Kotin, R.M. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002, 13: 1935-43.
42. Green, A.P., Huang, J.J., Scott, M.O. et al. A new scalable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 2002, 13: 1921-34.
43. Burns, J.C., Friedman, T., Driver, W. et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian cells. Proc Natl Acad Sci USA 1993, 90: 8033-7.
44. Zhang, B., Xia, H.Q., Cleghom, G. et al. A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Ther 2001, 8: 1745-51.
45. Vracken Peeters, M.J., Perkins, A.L. and Kay, M.A. Method for multiple portal vein infusion in mice: Quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 1996, 20: 278-85.
46. Ye, X., Gao, G.P., Pabin, C. et al. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998, 9: 2135-42.
47. Williams, D.A. and Smith, F.O. Progress in the use of gene transfer methods to treat genetic blood diseases. Hum Gene Ther 2000, 11: 2059-66.
48. Zennou, V., Petit, C., Guetard, D. et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000, 101: 173-85.
49. Stevenson, M. HIV nuclear import: What's the flap? Nat Med 2000, 6: 626-8.
50. Sirven, A., Pflumio, F., Zennou, V. et al. The human immunodeficiency virus type 1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000, 96: 4103-10.
51. Follenzi, A., Ailles, L.E., Bakovic, S. et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000, 25: 217-22.
52. Zennou, V., Serguera, C., Sarkis, C. et al. The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol 2001, 19: 446-50.
53. O'Rourke, J.P., Newbound, G.C., Kohn, D.B. et al. Comparison of gene transfer efficiency and gene expression levels achieved with equine infectious anemia virus and human immunodeficiency virus type 1-derived lentivirus vectors. J Virol 2002, 76: 1510-5.
54. Berkowitz, R.D., Ilves, H., Plavec, I. and Veres, G. Gene transfer systems derived from Visna virus:Analysis of virus production and infectivity. Virology 2001, 279: 116-29.
55. Podsakoff, G.M. Lentiviral vectors approach the clinic but fall back: National institutes of Health recombinant DNA advisory committee review of a first clinical protocol for use of a lentiviral vector. Mol Ther 2001, 4: 282-3.
56. Larsson, E. and Anderson, G. Beneficial role of human endogenous retroviruses: Facts and hypothesis. Scand J Immunol 1998, 48: 329-38.
57. Yang, J., Bogerd, H.P., Peng, S. et al. An ancient family of human endogenous retroviruses encodes for a functional homolog of the HIV-1 Rev protein. Proc Natl Acad Sci USA 1996, 96: 13404-8.
58. Malim, M.H., Hauber, J., Le, S.Y. et al. The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989, 338: 254-7.
59. Lower, R., Lower, J. and Kurth, R. The viruses in all of us: Characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 1996, 93: 5177-84.
60. Johnston, J.C., Gasmi, M., Lim, L.E. et al. Minimum requirement for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999, 73: 4991-5000.
61. Crystal, R.G. Bad for cats, good for humans? Modified immunodeficiency virus for gene delivery. J Clin Invest 1999, 104: 1491-3.
62. Matukonis, M., Li, M., Molina, R.P. et al. Development of second and third generation bovine immunodeficiency virus based gene transfer systems. Hum Gene Ther 2002, 13: 1293-303.
63. Takahashi, K., Luo, T., Saishin, Y. et al. Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 2002, 13: 1305-16.
64. Ikeda, Y., Collins, M.K.L., Radcliffe, P.A. et al. Gene transduction efficiency in cells of different species by HIV and EIAv vectors. Gene Ther 2002, 9: 932-8.
65. Mazarakis, N.D., Azzouz, M., Rohll, J.B. et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001, 10: 2109-21.
66. Whitwam, T., Peretz, M. and Poeschla, E. Identification of a central DNA flap in feline immunodeficiency virus. J Virol 2001, 75: 9407-14.
67. Bestor, T.H. Gene silencing as threat to the success of gene therapy. J Clin Invest 2000, 105: 409-11.
68. Kalberer, C.P., Pawliuk, R., Imren, S. et al. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of human beta-globin in engrafted mice. Proc Natl Acad Sci USA 2000, 97: 5411-5.
69. Klug, C.A., Cheshier, S. and Weissman, I.L. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 96: 894-901.
70. Rosenzweig, M., Connole, M., Glickman, R. et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells. Blood 2001, 97: 1951-9.
71. Huang, Y., Wimler, K.M. and Carmichel, G.G. Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing. Embo J 1999, 18: 1642-52.
72. Donello, J.E., Loeb, J.E. and Hope, T.J. Woodchuck hepatitis virus contains a tripartite post-transcriptional regulatory element. J Virol 1998, 72: 5085-92.
73. Paterna, J.C., Moccetti, T., Mura, A. et al. Influence of promoter and WHV post transcriptional regulatory elements on AAV mediated gene transgene expression in the rat brain. Gene Ther 2000, 7: 1304-11.
74. Weitzman, M.D., Kyostio, S.R., Kotin, R.M. et al. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994, 91: 5808-12.
75. Satoh, W., Hirai, Y., Takayose, K. et al. Site specific integration of an adeno associated virus vector plasmid mediated by regulated expression of Rep based on cre loxP recombination. J Virol 2000, 74: 10631-8.
76. Lieber, A., Steinwaerder, D.S., Carlson, C.A. et al. Integrating adenovirus adeno associated virus hybrid vectors devoid of all viral genes. J Virol 1999, 73: 9314-24.
77. Philpott, N.J., Giraud-Wali, C., Dupuis, C. et al. Efficient integration of recombinant adeno associated virus DNA vectors requires a p5-rep sequence in cis. J Virol 2002, 76: 5411-21.
78. Yu, S.F., von Ruden, T., Kantoff, P.W. et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986, 83: 3194-8.
79. Varmus, H. Getting ready for gene-based medicine. N Engl J Med 2002, 19: 1526-7.
80. Guttmacher, A.E. and Collins, F.S. Genomic medicine - a primer. N Engl J Med 2002, 19: 1512-20.
81. Romano, G., Reiss, K., Tu, X. et al. Efficient in vitro and in vivo gene regulation of a retrovirally delivered pro-apoptotic factor under the control of the Drosophila HSP70 promoter. Gene Ther 2001, 8: 600-7.
82. Wyman, T.C., Rohrer, D.C., Kirigiti, P. et al. Promoter activated expression of nerve growth factor for treatment of neurodegenerative diseases. Gene Ther 1999, 6: 1648-60.
83. Johansen, J., Rosenblad, C., Andsberg, K. et al. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS. Gene Ther 2002, 9: 1291-301.